Compounds > ubenimex
Page last updated: 2024-08-25

ubenimex and tosedostat

ubenimex has been researched along with tosedostat in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Singh, R; Vince, R; Williams, J1
Butler, GS; Charman, SA; Drinkwater, N; Gazdik, M; Grin, PM; Kannan Sivaraman, K; Lee, J; McGowan, S; Overall, CM; Scammells, PJ; Schembri, LS; Vinh, NB; Yang, W1
Ayscough, A; Bawden, LJ; Bone, EA; Box, G; Callaghan, J; Chandler, S; Clark, VL; Drummond, AH; Eccles, SA; Farmer, H; Flores, N; Kirwin-Jones, P; Krige, D; Laber, D; Legris, V; Miles, LE; Needham, LA; Odedra, R; Owen, J; Patel, T; Stone, E; Wood, LM; Wood, S; Wright, A1
Gullbo, J; Larsson, R; Nygren, P; Wickström, M1

Reviews

1 review(s) available for ubenimex and tosedostat

ArticleYear
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
    Cancer science, 2011, Volume: 102, Issue:3

    Topics: CD13 Antigens; Cell Proliferation; Clinical Trials as Topic; Glycine; Humans; Hydroxamic Acids; Leucine; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Prognosis; Protease Inhibitors

2011

Other Studies

4 other study(ies) available for ubenimex and tosedostat

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
    European journal of medicinal chemistry, 2017, Oct-20, Volume: 139

    Topics: Aminopeptidases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Hematologic Neoplasms; HL-60 Cells; Humans; Molecular Structure; Puromycin; Structure-Activity Relationship; Vero Cells

2017
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
    Journal of medicinal chemistry, 2019, 08-08, Volume: 62, Issue:15

    Topics: Animals; Binding Sites; CD13 Antigens; Drug Discovery; Enzyme Inhibitors; Humans; Male; Mice; Protein Binding; Protein Structure, Tertiary

2019
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
    Cancer research, 2008, Aug-15, Volume: 68, Issue:16

    Topics: Amino Acids; Aminopeptidases; Animals; Biomarkers, Tumor; Cell Proliferation; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Eukaryotic Initiation Factor-2; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Glycine; HL-60 Cells; Humans; Hydroxamic Acids; Immunoblotting; Leucine; Mice; Oligonucleotide Array Sequence Analysis; Peptide Fragments; Phenylalanine; Phosphorylation; Protein Kinases; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008